Development of SMEs and heterogeneity of trajectories: the case of biotechnology in France

Mangematin, Vincent; Lemarié, Stéphane; Boissin, Jean‐Pierre; Catherine, David; Corolleur, Frédéric; Coronini, Roger; Trommetter, Michel

doi:10.1016/s0048-7333(02)00045-8

Cited by 183 publications

(130 citation statements)

References 23 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Close contact with competitors, or colleague firms, allows SMEs to be at the forefront of new market developments that are taking place, and participate with other firms in innovation cooperation or partnerships. For example, Mangematin et al 2003 show that biotechnology SMEs typically enter into contracts with big industrial groups or run small projects, manufacturing their own products and marketing them. A development that was already highlighted by Hamel et al (1989), who also argued that successful companies (in their study primarily Asian) use alliances with competitors not only to avoid investments but to build skills in areas outside the formal agreement and, in this way, systematically diffuse new knowledge throughout their organizations.…”

Section: Effect Of Cs On Ipmentioning

confidence: 99%

From innovation to commercialization through networks and agglomerations: analysis of sources of innovation, innovation capabilities and performance of Dutch SMEs

2012

View full text Add to dashboard Cite

This study claims that policy makers may not be sufficiently aware of the importance of maintaining an appropriate balance between exploration and exploitation networks for small and medium-sized enterprises (SMEs). On the basis of the open innovation model, policy makers are also increasingly stimulating SMEs to develop their exploration skills. In the Netherlands, a government subsidy called the 'innovation voucher programme' was introduced to stimulate SMEs to develop innovation in cooperation with knowledge institutes. Yet, although many studies show that SMEs tend to have a higher R&D productivity than larger firms, and innovative SMEs are more likely to make external networks with other SMEs or institutions such as universities, there is still little examination of the successfulness of SME's innovation activities. The growing policy attention for the role of SMEs in innovation prompts the questions how innovation in SMEs can be facilitated, and which factors contribute to the success (or failure) of their innovation efforts. This study explores the innovation strategy of innovative Dutch SMEs by means of their sources of innovation, innovation capabilities, innovation performance, and commercialization sources. By means of structural equation modelling of a sample of 243 Dutch SMEs, this study shows that exploring (technology) opportunity together with institutions such as universities and private research establishments is important for successful innovation in SMEs. But, in addition, our model shows that contacts with competitors are also important for successful innovation performance. Our finding that openness of open innovation also applies to the commercialization phase is too often neglected by researchers and policy makers. JEL Classification

show abstract

Section: Effect Of Cs On Ipmentioning

confidence: 99%

From innovation to commercialization through networks and agglomerations: analysis of sources of innovation, innovation capabilities and performance of Dutch SMEs

2012

View full text Add to dashboard Cite

show abstract

“…The pattern of biotechnology development has largely been based on the creation of research-intensive SMEs (Orsenigo, 1989(Orsenigo, , 2001Gambardella, 1995;Sharp 1985, Kenney, 1986, usually university spin-offs formed through the collaboration of a scientist and a professional manager, backed by venture capital, with the aim of applying new scientific discoveries to commercial product development (Mangematin et al 2003). In many cases these spin-offs benefited from access to top world experts (usually university scientists) on specific topics, and the firms" expertise has essentially been in research areas directly related to the scientific field of their expert"s original laboratory.…”

Section: Comparing Nanotechnology With Biotechnologymentioning

confidence: 99%

“…So these collaborative arrangements between small and large firms provided both partners with access to the competences and assets they lacked: large companies to the SMEs" scientific discoveries -and the potential of receiving royalties if they had commercial potential -and SMEs to commercial markets. Consequently, the biotechnology industry is characterized by a network structure of inter-organizational alliances among the different actors involved: research institutions and large and small-medium firms, in which the latter are seen as a nexus, mediating between the scientists and the large established commercial players (Mangematin et al 2003). …”

Section: Comparing Nanotechnology With Biotechnologymentioning

confidence: 99%

Which model of technology transfer for nanotechnology? A comparison with biotech and microelectronics

2012

View full text Add to dashboard Cite

Abstract.Nanotechnologies are often presented as breakthrough innovations, where technology transfer and knowledge-bridging will play a pivotal role in the industrial dynamics. This article investigates the model of knowledge transfer in the nanotechnologies in depth, by comparing it with the models of two recently emerged technologies: biotech and microelectronics. Our results show that the nanotechnology transfer model is very different from that involved in biotechnology evolution: while small-medium firms play a valuable technology-bringing role, the central function of "translating" new knowledge between public research and industry in carried by the larger firms, just as it was in the early stages of the microelectronics sector.

show abstract

“…The development of the biotechnology sector is based on the emergence of a large number of small-and medium-sized enterprises (SMEs). The novelty and diversity based on the life sciences allowed the emergence of new firms [2] and the development of the biotech sector is based on the entry of a large number of small and medium-sized enterprises (SMEs) [3]. Many researchers focus on fast-growing SMEs as a key mechanism in the sector's development [3].…”

Section: Introductionmentioning

confidence: 99%

“…The novelty and diversity based on the life sciences allowed the emergence of new firms [2] and the development of the biotech sector is based on the entry of a large number of small and medium-sized enterprises (SMEs) [3]. Many researchers focus on fast-growing SMEs as a key mechanism in the sector's development [3]. Biotech SMEs enter into linkages with external entities to acquire resources they lack such as finance resources.…”

Section: Introductionmentioning

confidence: 99%

The Role of Venture Capital on Innovation in the Korean Biotechnology Industry

Sohn¹,

Kang²

2015

IJTEF

View full text Add to dashboard Cite

Abstract-Venture capital financing is generally considered as the most suitable external financing mode for New technology based SMEs, such as biotech SMEs. However, the way in which venture capital investments influence a firm's innovation performance is not as certain. In this paper, we empirically analyzed the impact of venture capital investments on networks and innovation performance in Korean biotech SMEs. Venture capital investment was positively associated with downstream partnerships, supporting Hypothesis 1-2 (β=0.29, p<0.001). Inter-firm collaborations were positively correlated with a firm's innovation performance, supporting Hypothesis 2 (β=0.18, p<0.10 in upstream partnerships, β=0.61, p<0.01 in downstream partnerships). This study showed the mechanism of venture capital investment influencing innovation by promoting downstream collaborations.

show abstract

Development of SMEs and heterogeneity of trajectories: the case of biotechnology in France

Cited by 183 publications

References 23 publications

From innovation to commercialization through networks and agglomerations: analysis of sources of innovation, innovation capabilities and performance of Dutch SMEs

From innovation to commercialization through networks and agglomerations: analysis of sources of innovation, innovation capabilities and performance of Dutch SMEs

Which model of technology transfer for nanotechnology? A comparison with biotech and microelectronics

The Role of Venture Capital on Innovation in the Korean Biotechnology Industry

Contact Info

Product

Resources

About